MCID: NSL008
MIFTS: 48

Nasal Cavity Cancer

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Cancer

MalaCards integrated aliases for Nasal Cavity Cancer:

Name: Nasal Cavity Cancer 12 15
Nasal Cavity Carcinoma 12 15 74
Malignant Neoplasm of Nasal Cavities 12
Malignant Tumor of the Nasal Cavity 12
Malignant Neoplasm of Nasal Cavity 74
Carcinoma of Nasal Cavity 12
Neoplasm of Nasal Cavity 74
Cancer of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10811 DOID:4931
ICD9CM 36 160.0
NCIt 51 C4918 C9336
SNOMED-CT 69 93917007
ICD10 34 C30.0

Summaries for Nasal Cavity Cancer

Disease Ontology : 12 A nasal cavity cancer that_has material basis in epithelial cells.

MalaCards based summary : Nasal Cavity Cancer, also known as nasal cavity carcinoma, is related to inverted papilloma and epithelial-myoepithelial carcinoma, and has symptoms including pain and rhinorrhea. An important gene associated with Nasal Cavity Cancer is CXCL11 (C-X-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are Gastric cancer and Development HGF signaling pathway. The drugs Bupropion and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include liver, ovary and prostate, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Nasal Cavity Cancer

Diseases in the Nasal Cavity Cancer family:

Nasal Cavity Carcinoma in Situ

Diseases related to Nasal Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 30.3 CDKN2A KRT7 TP53
2 epithelial-myoepithelial carcinoma 30.3 HRAS KRT7 TP53
3 nasal cavity adenocarcinoma 30.3 CCK CDKN2A CDX2 CXCL11 GAST HRAS
4 papilloma 30.0 CDKN2A KRT5 KRT7 KRT8 TP53
5 adenoid cystic carcinoma 29.8 HRAS KRAS KRT5 KRT7 TP53
6 nasal cavity squamous cell carcinoma 29.3 ANKRD11 CDKN2A CXCL11 FRS2 KRT5 KRT7
7 nasal cavity carcinoma in situ 12.4
8 nasal cavity cancer, childhood 12.4
9 ovary neuroendocrine neoplasm 10.5 CDX2 KRT7
10 proliferating trichilemmal cyst 10.5 KRT7 KRT8
11 endolymphatic sac tumor 10.5 KRT7 KRT8
12 appendix adenocarcinoma 10.4 CDX2 KRT7
13 benign breast adenomyoepithelioma 10.4 KRT5 KRT7
14 ceruminoma 10.4 KRT5 KRT7
15 mucinous adenofibroma 10.4 CDX2 KRT7
16 olfactory neuroblastoma 10.4
17 middle ear carcinoma 10.4
18 anus adenocarcinoma 10.4 CDX2 KRT7
19 calcifying epithelial odontogenic tumor 10.4 KRT8 TP53
20 glandular cystitis 10.4 CDX2 KRT7
21 vulva adenocarcinoma 10.4 CDKN2A CDX2 KRT7
22 inverted transitional papilloma 10.4 CDKN2A KRT5 KRT7
23 mucinous bronchioloalveolar adenocarcinoma 10.4 CDKN2A CDX2 KRT7
24 bladder carcinoma in situ 10.4 CDKN2A KRT7 TP53
25 apocrine sweat gland neoplasm 10.4 KRT5 KRT7 KRT8
26 vulvar intraepithelial neoplasia 10.4 KRT7 TP53
27 pleomorphic carcinoma 10.4 KRT7 KRT8 TP53
28 vulvar disease 10.4 CDKN2A KRT7 TP53
29 benign mesothelioma 10.4 KRT5 KRT7
30 glycogen-rich clear cell breast carcinoma 10.4 CDKN2A KRT7 TP53
31 gastric tubular adenocarcinoma 10.4 CDX2 KRT7 KRT8
32 lymphoepithelioma-like carcinoma 10.4 KRT5 KRT7 KRT8
33 atypical choroid plexus papilloma 10.4 KRT5 KRT7 KRT8
34 breast secretory carcinoma 10.4 KRT5 KRT7 KRT8
35 malignant spiradenoma 10.4 KRT5 KRT7 TP53
36 pregnancy adenoma 10.4 KRT5 KRT7 KRT8
37 appendix cancer 10.4 CDX2 KRT7 TP53
38 cystic teratoma 10.4 CDX2 KRT7 TP53
39 teratoma 10.4 CDX2 KRT7 TP53
40 intraneural perineurioma 10.4 KRT5 KRT7 KRT8
41 bladder adenocarcinoma 10.4 CDX2 HRAS KRT7
42 vulva cancer 10.3 CDKN2A KRT7 TP53
43 neurenteric cyst 10.3 KRAS KRT8
44 eccrine sweat gland neoplasm 10.3 KRT5 KRT7 TP53
45 pancreatic ductal carcinoma 10.3 CDKN2A KRT7 TP53
46 keratinizing squamous cell carcinoma 10.3 CDKN2A KRT5 TP53
47 cystitis cystica 10.3 CDX2 KRT5 KRT7
48 primary cutaneous amyloidosis 10.3 KRT5 KRT7 KRT8
49 spitz nevus 10.3 CDKN2A HRAS TP53
50 small cell carcinoma 10.3 CDKN2A KRT7 TP53

Graphical network of the top 20 diseases related to Nasal Cavity Cancer:



Diseases related to Nasal Cavity Cancer

Symptoms & Phenotypes for Nasal Cavity Cancer

UMLS symptoms related to Nasal Cavity Cancer:


pain, rhinorrhea

MGI Mouse Phenotypes related to Nasal Cavity Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 ANKRD11 CDKN2A CDX2 FRS2 HRAS KIDINS220
2 homeostasis/metabolism MP:0005376 10.21 ANKRD11 CCK CDKN2A CDX2 GAST HRAS
3 cardiovascular system MP:0005385 10.18 CDKN2A CDX2 FRS2 HRAS KIDINS220 KRAS
4 mortality/aging MP:0010768 10.13 ANKRD11 CDKN2A CDX2 FRS2 GAST HRAS
5 digestive/alimentary MP:0005381 10.11 CDKN2A CDX2 GAST HRAS KRAS KRT5
6 embryo MP:0005380 10.03 ANKRD11 CDKN2A CDX2 FRS2 KRAS KRT8
7 no phenotypic analysis MP:0003012 9.81 CCK CDKN2A HRAS KIDINS220 KRAS KRT5
8 neoplasm MP:0002006 9.8 CDKN2A CDX2 GAST HRAS KRAS TIMP1
9 renal/urinary system MP:0005367 9.43 CCK HRAS KRAS KRT7 SLC25A19 TP53
10 skeleton MP:0005390 9.28 ANKRD11 CDKN2A CDX2 FRS2 HRAS KRAS

Drugs & Therapeutics for Nasal Cavity Cancer

Drugs for Nasal Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
2
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
3
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
4 Liver Extracts Phase 4,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
6 Dopamine Uptake Inhibitors Phase 4,Phase 2
7 Antidepressive Agents Phase 4,Phase 2
8 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
9 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
10 Psychotropic Drugs Phase 4,Phase 2
11 Dopamine Agents Phase 4,Phase 2
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
13 Antidepressive Agents, Second-Generation Phase 4,Phase 2
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Central Nervous System Stimulants Phase 4,Not Applicable
16 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Nicotinic Agonists Phase 4,Not Applicable
18 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
19
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
20
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
21
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
22
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
23
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
24
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
25 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
26 Antimetabolites Phase 3,Phase 1,Phase 2
27 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
28 Immunologic Factors Phase 3,Phase 1,Phase 2
29 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
31 Muscarinic Agonists Phase 2, Phase 3
32
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable 33069-62-4 36314
33
Amifostine Approved, Investigational Phase 1, Phase 2,Phase 2 20537-88-6 2141
34
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
35
Indinavir Approved Phase 2 150378-17-9 5362440
36
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
37
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
38
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
39 Raspberry Approved Phase 1, Phase 2
40
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
41
Zinc oxide Approved Phase 2 1314-13-2
42
Zinc Approved, Investigational Phase 2 7440-66-6 32051
43
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
44
Ipilimumab Approved Phase 2 477202-00-9
45
nivolumab Approved Phase 2 946414-94-4
46 Radiation-Protective Agents Phase 1, Phase 2,Phase 2
47 Albumin-Bound Paclitaxel Phase 1, Phase 2,Phase 2,Not Applicable
48 Protective Agents Phase 1, Phase 2,Phase 2
49 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2,Not Applicable
50 Antiviral Agents Phase 1, Phase 2,Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
4 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
5 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
6 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
7 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
8 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
9 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
12 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
13 Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
14 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
15 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract Completed NCT00524017 Phase 2
16 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2 bupropion hydrochloride
17 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
18 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
19 Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer Recruiting NCT00707473 Phase 2 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
20 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
21 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
22 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
23 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Unknown status NCT00004097 Phase 1 fluorouracil;gemcitabine hydrochloride;paclitaxel
24 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
25 Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors Completed NCT00978081 Phase 1 aminolevulinic acid hydrochloride
26 L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors Completed NCT00003430 Phase 1 L-778,123
27 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
28 ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
29 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Unknown status NCT01254591 Not Applicable
30 Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses Completed NCT00797498
31 Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer Completed NCT00019201 Not Applicable
32 Acceptability of Less Harmful Alternatives to Cigarettes Completed NCT00957424 Not Applicable nicotine replacement therapy
33 Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking Completed NCT00790569 Not Applicable nicotine;varenicline
34 Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic Completed NCT00533884
35 Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy Completed NCT00310115
36 Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking Completed NCT00021138 Not Applicable nicotine
37 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
38 Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer Recruiting NCT02589938 Not Applicable
39 Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers Recruiting NCT00900419
40 Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use Active, not recruiting NCT00799669
41 Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure Active, not recruiting NCT00530049
42 Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Terminated NCT00623129 Not Applicable
43 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors Withdrawn NCT00499291 Not Applicable paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Nasal Cavity Cancer

Genetic Tests for Nasal Cavity Cancer

Anatomical Context for Nasal Cavity Cancer

MalaCards organs/tissues related to Nasal Cavity Cancer:

42
Liver, Ovary, Prostate, Appendix, Brain, Pancreas, Thyroid

Publications for Nasal Cavity Cancer

Articles related to Nasal Cavity Cancer:

# Title Authors Year
1
(P092) definitive chemoradiotherapy or radiotherapy for unresectable, very locally advanced, or medically inoperable paranasal sinus and nasal cavity cancer. ( 25930909 )
2015
2
Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. ( 18705398 )
2008
3
Prognostic factors in maxillary sinus and nasal cavity carcinoma. ( 15923101 )
2005
4
Ethmoid and upper nasal cavity carcinoma: treatment, results and complications. ( 2123986 )
1990
5
Nasal obstruction portending nasal cavity cancer. ( 2599810 )
1989
6
Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. ( 3810867 )
1986

Variations for Nasal Cavity Cancer

Expression for Nasal Cavity Cancer

Search GEO for disease gene expression data for Nasal Cavity Cancer.

Pathways for Nasal Cavity Cancer

Pathways related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 CDKN2A CDX2 HRAS KRAS TP53
2
Show member pathways
12.4 FRS2 HRAS KIDINS220 KRAS TP53
3 12.17 CDKN2A HRAS KRAS TP53
4
Show member pathways
12.05 HRAS KRAS TIMP1 TP53
5 12.04 FRS2 HRAS KRAS TP53
6 12.01 CDKN2A HRAS KRAS TP53
7 11.76 CDKN2A HRAS KRAS TP53
8
Show member pathways
11.67 FRS2 HRAS KRAS
9 11.52 CDKN2A HRAS KRAS TP53
10 11.47 HRAS KRAS TP53
11 11.45 HRAS KRAS TP53
12 11.3 CDKN2A HRAS KRAS TP53
13 11.15 HRAS KRAS TP53
14 10.79 CDKN2A HRAS KRAS TP53
15 10.66 HRAS KRAS
16 10.17 CCK GAST

GO Terms for Nasal Cavity Cancer

Biological processes related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 CCK CDX2 HRAS KRAS TIMP1
2 regulation of signaling receptor activity GO:0010469 9.72 CCK CXCL11 GAST PDYN TIMP1
3 replicative senescence GO:0090399 9.37 CDKN2A TP53
4 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.26 TIMP1 TIMP2
5 response to isolation stress GO:0035900 9.16 HRAS KRAS
6 negative regulation of metallopeptidase activity GO:1905049 8.96 TIMP1 TIMP2
7 Ras protein signal transduction GO:0007265 8.92 CDKN2A HRAS KRAS TP53

Sources for Nasal Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....